Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
Mitesh J Borad, Gregory J Gores, Lewis R Roberts, Mitesh J Borad, Gregory J Gores, Lewis R Roberts
Abstract
Purpose of review: This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA).
Recent findings: Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed.
Summary: Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.
Trial registration: ClinicalTrials.gov NCT02150967 NCT02265341.
Conflict of interest statement
Conflicts of interest
There are no conflicts of interest.
Source: PubMed